3-(氯甲基)吡唑盐酸盐 | 69658-97-5

• 物质功能分类: 医药中间体 - 杂环化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 3-(氯甲基)吡唑盐酸盐
• 中文别名: 3-氯甲基-1H-吡唑
• 英文名称: 3-(chloromethyl)-1H-pyrazole hydrochloride
• 英文别名: 3-(chloromethyl)pyrazole hydrochloride；5-(chloromethyl)-1H-pyrazole;hydrochloride
• CAS: 69658-97-5
• 化学式: C₄H₆ClN₂*Cl
• mdl: MFCD08234808
• 分子量: 153.011
• InChiKey: IPKKDQOUBFUVGT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.78
• 重原子数：
  8
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  28.7
• 氢给体数：
  2
• 氢受体数：
  1

安全信息

• 海关编码：
  2933199090
• 包装等级：
  III
• 危险类别：
  8
• 危险性防范说明：
  P280,P305+P351+P338,P310
• 危险品运输编号：
  1759
• 危险性描述：
  H302,H314
• 储存条件：
  室温且干燥

反应信息

• 作为反应物：
  描述：

  N-丁基咪唑 、 3-(氯甲基)吡唑盐酸盐 在 Amberlite IRA 401,hydroxide form 、 tetrafluoroboric acid 作用下， 以 乙醇 、 乙醚 为溶剂， 反应 0.5h， 以18%的产率得到
  参考文献：
  名称：

  Selection of Betaine Building Blocks for the Construction of Quadrupolar Heterophane Frameworks

  摘要：

  The synthesis of a set of [(azolio)methyl]azolate betaines 3-6 designed by combination of a variety of heterocyclic fragments based on pyrazole, 1,2,4-triazole, and benzimidazole is reported. The dipolar nature of the betaines is discussed on the basis of H-1 and C-13 NMR spectroscopic data and dipole moment values, which range between 13.4 and 16.5 D. By exploitation of the sensitivity of electrospray ionization mass spectrometry in both the positive and negative modes, several informative peaks and stable noncovalent polymolecular self-assembled structures in the gas phase were observed. From these results, the [(imidazolio)mettyl]-1,2,4-triazolate betaine subunits 1 were chosen as the most suitable building blocks for the construction of quadrupolar [1(n)]heterophanes. (C) Wiley-VCH Verlag GmbH, 69451 Weinheim, Germany, 2002.

  DOI：

  10.1002/1099-0690(200208)2002:16<2691::aid-ejoc2691>3.0.co;2-t

文献信息

• [EN] HYDROXAMATE COMPOUNDS AS ANTAGONISTS OF THE ADENOSINE A2A RECEPTOR<br/>[FR] COMPOSÉS HYDROXAMATE EN TANT QU'ANTAGONISTES DU RÉCEPTEUR A2A DE L'ADÉNOSINE
  申请人：ADORX THERAPEUTICS LTD

  公开号：WO2020260857A1

  公开（公告）日：2020-12-30

  The present invention relates to compounds of formula I shown below: (I) wherein R1, R2 and R3 are each as defined in the application. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of diseases or conditions in which adenosine A2a receptor activity is implicated, such as, for example, cancer.

  本发明涉及下面所示的式I的化合物：(I)，其中R1、R2和R3在申请中各自定义。本发明还涉及制备这些化合物的方法，包括含有它们的药物组合物，以及它们在治疗腺苷A2a受体活性参与的疾病或症状中的用途，例如癌症。
• [EN] INHIBITORS OF CBL-B AND METHODS OF USE THEREOF<br/>[FR] INHIBITEURS DE CBL-B ET LEURS PROCÉDÉS D'UTILISATION
  申请人：NURIX THERAPEUTICS INC

  公开号：WO2019148005A1

  公开（公告）日：2019-08-01

  Compounds, compositions, and methods for use in inhibiting the E3 enzyme Cbl-b in the ubiquitin proteasome pathway are disclosed. The compounds, compositions, and methods can be used to modulate the immune system, to treat diseases amenable to immune system modulation, and for treatment of cells in vivo, in vitro, or ex vivo.

  揭示了用于抑制泛素蛋白酶体途径中的E3酶Cbl-b的化合物、组合物和使用方法。这些化合物、组合物和方法可用于调节免疫系统，治疗适合免疫系统调节的疾病，并用于体内、体外或体外细胞的治疗。
• [EN] COMPOUNDS AND METHODS OF USE<br/>[FR] COMPOSÉS ET PROCÉDÉS D'UTILISATION
  申请人：TANGO THERAPEUTICS INC

  公开号：WO2021086879A1

  公开（公告）日：2021-05-06

  Compounds are provided according to Formula (I): and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof; wherein X1, X2, X3, X4, X5, A, L, R1, R2, R5, m and n are as defined herein. Compounds of the present invention are contemplated useful for the prevention and treatment of a variety of conditions.

  根据公式（I）提供化合物及其药学上可接受的盐，以及药物组合物；其中X1、X2、X3、X4、X5、A、L、R1、R2、R5、m和n的定义如本文所述。本发明的化合物被认为对预防和治疗各种疾病条件有用。
• [EN] PYRAZOLES<br/>[FR] PYRAZOLES
  申请人：JANSSEN PHARMACEUTICALS INC

  公开号：WO2016025918A1

  公开（公告）日：2016-02-18

  The invention relates to pyrazole derivatives which are NMDA NR2B receptor inhibitors, useful in treating central nervous system diseases.

  这项发明涉及吡唑衍生物，它们是NMDA NR2B受体抑制剂，可用于治疗中枢神经系统疾病。
• [EN] SUBSTITUTED HETEROAROMATIC PYRAZOLO-PYRIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS<br/>[FR] PYRAZOLO-PYRIDINES HÉTÉROAROMATIQUES SUBSTITUÉES ET LEUR UTILISATION EN TANT QUE MODULATEURS DU RÉCEPTEUR GLUN2B
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2020249785A1

  公开（公告）日：2020-12-17

  Substituted Pyrazolo-pyridines as GluN2B receptor ligands. Such compounds may be used in GluN2B receptor modulation and in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by GluN2B receptor activity.

  替代性吡唑并吡啶作为GluN2B受体配体。此类化合物可用于GluN2B受体调节，以及用于治疗由GluN2B受体活性介导的疾病状态、紊乱和条件的药物组合物和方法。